Evidence map›Paper›PMID 42031955›Full record

ArticleScientific reports2026

An eye drop combination for treating Staphylococcus aureus-induced keratitis in rats: repurposing ibuprofen.

Nevine L Seiffein, Maher Abdel-Nabi Kamel, Ghada Hani Ali, Lamia Said Kandil, Amani Kazem, Sherien A Abdelhady

Abstract read
In one paragraph

Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Nevine L SeiffeinDepartment of Microbiology and Immunology, Faculty of Pharmacy, Pharos University in Alexandria, Canal El Mahmoudia Street, Beside Green Plaza Complex 21648, Alexandria, Egypt.
Maher Abdel-Nabi KamelDepartment of Biochemistry, Medical Research Institute, Alexandria University, Alexandria, Egypt.
Ghada Hani AliDepartment of Pharmacy, Alexandria Main Hospital, Alexandria, Egypt.
Lamia Said KandilSchool of Pharmacy and Biomedical Sciences, University of Lancashire, Preston, UK.
Amani KazemDepartment of Pathology, Medical Research Institute, Alexandria University, Alexandria, Egypt.
Sherien A AbdelhadyDepartment of Pharmacology and Biochemistry, Faculty of Pharmacy, Horus University in Egypt, New Damietta, Egypt. Shabdelhady@horus.edu.eg.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Infectious keratitis is a life-hindering disease that has been one of the leading causes of blindness worldwide. The current study aimed to test a combination of levofloxacin and ibuprofen for treating Staphylococcus aureus-associated keratitis, with special emphasis on the potential antimicrobial and antibiofilm activities of the non-steroidal anti-inflammatory drug (NSAID) moiety. keratitis was induced in male Sprague Dawley rats by abrasion in the right eye after topical anesthesia, then the wounded eyes were inoculated with a 10 µl aliquot containing Staphylococcus aureus. Rats were divided into five groups: control, infected keratitis rats, infected keratitis rats treated with 0.5% levofloxacin, infected keratitis rats treated with 0.3% ibuprofen, and infected keratitis rats treated with 0.5% levofloxacin + 0.3% ibuprofen. Treatments were given as eye drops for two weeks. Then, the corneal tissues were isolated for investigations. The molecular study showed that, among the four groups, rats treated with combined eye therapy of 0.5% levofloxacin + 0.3% ibuprofen had the lowest expression levels of inflammatory mediators, metalloproteinases, corneal angiogenesis, and the proapoptotic BCL2-associated X (Bax). Histological investigation confirmed the transcriptional changes, with the rats that received combined eye therapy showing the best therapeutic outcomes.

Indexed as

IbuprofenKeratitisOphthalmic SolutionsStaphylococcal InfectionsStaphylococcus aureusAnimalsAnti-Bacterial AgentsAnti-Inflammatory Agents, Non-Steroidalbcl-2-Associated X ProteinCorneaDisease Models, AnimalDrug RepositioningDrug Therapy, CombinationLevofloxacinMaleRatsAnti-Bacterial AgentsAnti-Inflammatory Agents, Non-Steroidalbcl-2-Associated X ProteinIbuprofenLevofloxacinOphthalmic SolutionsBacterial keratitisIbuprofenIL-1βLevofloxacinMMPsTLR4

Identifiers

PMID42031955
PMCPMC13109396

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.